Matthew W. Foehr
2020 - Ligand Pharmaceuticals
In 2020, Matthew W. Foehr earned a total compensation of $3.5M as President and Chief Operating Officer at Ligand Pharmaceuticals, a 18% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $277,063 |
|---|---|
| Option Awards | $1,303,366 |
| Salary | $503,750 |
| Stock Awards | $1,242,269 |
| Other | $158,001 |
| Total | $3,484,449 |
Foehr received $1.3M in option awards, accounting for 37% of the total pay in 2020.
Foehr also received $277.1K in non-equity incentive plan, $503.8K in salary, $1.2M in stock awards and $158K in other compensation.
Rankings
In 2020, Matthew W. Foehr's compensation ranked 3,333rd out of 13,090 executives tracked by ExecPay. In other words, Foehr earned more than 74.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,333 out of 13,090 | 75th |
Division Manufacturing | 1,294 out of 5,621 | 77th |
Major group Chemicals And Allied Products | 489 out of 2,254 | 78th |
Industry group Drugs | 424 out of 1,954 | 78th |
Industry Pharmaceutical Preparations | 318 out of 1,459 | 78th |
Source: SEC filing on April 22, 2022.
Foehr's colleagues
We found three more compensation records of executives who worked with Matthew W. Foehr at Ligand Pharmaceuticals in 2020.